Structuring Cross‑border Joint Ventures and Minority Investments in Spain (2026): a Practical Guide for Tech & Life‑sciences Deals

Joint ventures Spain deals have become one of the most efficient ways for foreign strategic and financial investors to enter the Spanish market in 2026, particularly in technology and life sciences where regulatory scrutiny is rising and full acquisitions carry more friction. With Spanish M&A activity strong this year and foreign‑investment screening tightening under both national and EU rules, parties are increasingly using joint ventures and minority investments as lower‑risk instruments to gain exposure, share development cost and de‑risk market entry. This article is a practitioner playbook: it walks through structuring options, the legal and regulatory checklist, clause‑level drafting for shareholder agreements, and sector‑specific issues for MedTech, pharma, AI and software targets.

For a broader view of practitioners and capabilities, see Spain M&A: M&A lawyers & practice (Spain).

Executive summary & market context, Why joint ventures Spain deals make sense now

Spain’s M&A market has been buoyant in 2026, with reported deal capital rising materially year‑on‑year (industry reporting). That uplift, combined with a tougher foreign direct investment (FDI) regime and heavier sector‑specific scrutiny in tech and health, has pushed dealmakers toward structures that offer participation without the exposure of a full buyout. Joint ventures and minority investments allow investors to co‑develop products, access local know‑how and regulatory footprint, and defer the timing and cost of a complete acquisition.

Will 2026 be a good year for M&A in Spain? The available market data points to a healthy environment, but with a caveat. The same conditions driving deal volume (capital availability, sector convergence in digital health and AI) are the ones attracting closer regulatory attention. For cross‑border investors, the practical implication is that structuring and pre‑filing strategy matter more than ever.

At a high level, the choice between a joint venture and a minority investment turns on the following:

• Choose a JV when both parties will contribute assets, IP or a business line and expect joint management and shared upside.
• Choose a minority stake when speed, limited governance obligations and lower capital commitment are priorities.
• Consider a JV where co‑development of technology or clinical assets requires deep operational integration.
• Consider a minority stake where the investor wants optionality and a staged path to control.
• Weigh regulatory exposure: a JV with independent economic activity may trigger merger control; a passive minority stake may not.
• Weigh exit flexibility: minority positions rely heavily on contractual exit rights (tag, drag, ROFR); JVs need robust deadlock and buy‑out mechanics.

Legal & regulatory checklist for cross‑border joint ventures Spain and minority investments

Spanish corporate law provides the backbone for both JVs and minority investments. The core statute is the Ley de Sociedades de Capital (Capital Companies Act), the consolidated text published through the BOE, which governs the two principal vehicles, the Sociedad Limitada (SL) and the Sociedad Anónima (SA), as well as shareholder rights, board duties, capital increases and minority protections. Corporate reorganisations and cross‑border operations are additionally governed by the framework on structural modifications of companies. A cross‑border joint venture spain structure can be built as an incorporated company, a contractual (unincorporated) JV, or through a holding arrangement.

Whichever form is chosen, the regulatory checklist below applies in parallel with the corporate documentation, and several of these gates must be cleared before signing or closing.

The full regulatory perimeter for a tech or life‑sciences transaction typically covers:

• Corporate law. Formation, capital contributions, shareholder rights and reserved‑matter mechanics under the Ley de Sociedades de Capital (BOE).
• FDI screening. Foreign‑investment authorisation for sensitive sectors under the Spanish regime and Regulation (EU) 2019/452 (EUR‑Lex).
• Competition / merger control. Notification to the CNMC or the European Commission where turnover thresholds are met and the JV is full‑function.
• Sector licences. AEMPS authorisations for pharma and medical devices; telecoms and data‑centre permits for infrastructure.
• Data protection. AEPD compliance, including lawful bases and international transfer safeguards for personal and health data.
• Export controls / dual‑use. Screening for technology with dual‑use applications.
• Public procurement. Where the target holds or bids for public contracts, change‑of‑control provisions may apply.

FDI screening for joint ventures Spain: thresholds, timeline & practical mitigations

Spain operates a foreign direct investment screening regime that sits alongside the EU cooperation framework established by Regulation (EU) 2019/452 (EUR‑Lex). Screening focuses on investments into strategic and sensitive sectors, including critical technologies, dual‑use items, data infrastructure and, increasingly, health and biotech assets. Filings are made through the channels administered under the ministry responsible for trade and investment (see mincotur.gob.es), and clearance may be a condition precedent to completing the transaction. Note that the scope and thresholds of the regime, including the treatment of EU/EEA versus non‑EU/EEA investors, have been the subject of ongoing reform, so confirm the current rules before filing.

Timelines are case‑dependent, with statutory review windows that can be extended where the authority seeks further information or where remedies are negotiated. Because the exact filing trigger depends on the sector, the acquirer’s origin and the size of the stake, early engagement with the authority is the single most reliable way to control the calendar.

Practical pre‑transaction FDI screening checklist:

1. Map the target’s activities against Spain’s sensitive‑sector list and the EU framework.
2. Identify the investor’s ultimate beneficial ownership and any non‑EU control chain.
3. Assess whether the stake or governance rights cross the screening threshold.
4. Consider structuring options, a holdco layer, IP carve‑outs, or capped governance rights, that may keep a passive minority stake below the notification trigger, where legitimately available.
5. Build FDI clearance into the SPA/JV agreement as a condition precedent, with allocation of long‑stop risk.
6. Prepare mitigation undertakings (security covenants, data‑localisation commitments) in advance for sensitive assets.

Competition & merger control: when a JV may trigger notification

A joint venture may require merger‑control clearance where it performs, on a lasting basis, all the functions of an autonomous economic entity (a “full‑function” JV) and the parties’ turnover or market share meets the applicable thresholds. Clearance may be sought from the Comisión Nacional de los Mercados y la Competencia (CNMC) for Spanish concentrations, or from the European Commission where EU thresholds are met. Where the JV is purely contractual and does not create an autonomous business, for example, a co‑development arrangement with no standalone market presence, merger notification may not be triggered, though the cooperation may still raise antitrust considerations under the general prohibition on restrictive agreements. Assess this early, because a notifiable concentration cannot be implemented before clearance.

Sector licences & regulatory approvals (MedTech, pharma, AI)

Life‑sciences joint ventures carry a distinct regulatory layer. The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) regulates manufacturing, distribution and marketing authorisations for medicines and medical devices, and licences are frequently entity‑specific, meaning a change of control, or the contribution of a licensed activity into a new JV vehicle, may require notification, transfer or fresh authorisation. In a JV structuring tech spain context, AI and software targets rarely need a single “AI licence,” but they can attract obligations around data governance, cybersecurity and, for regulated end‑uses (health, finance, critical infrastructure), sector authorisations; note also the phased application of the EU Artificial Intelligence Act. Telecoms and data‑centre assets require their own permits.

The practical rule: identify every licence the target relies on, confirm whether it survives the transaction, and sequence approvals so operations are never interrupted at closing.

Data, privacy & cross‑border transfers

Data is often the most valuable and most sensitive asset in a tech or life‑sciences deal. The Agencia Española de Protección de Datos (AEPD) enforces data‑protection obligations in Spain under the GDPR and the Spanish data‑protection framework, and JVs that pool customer data, health records or clinical datasets must establish a lawful basis for processing, clear controller/processor roles, and compliant safeguards for any international transfers to the investor’s home jurisdiction. Health data is a special category attracting heightened protection. Build a data map into due diligence and address transfer mechanics and joint‑controllership arrangements directly in the transaction documents.

Choice of vehicle & tax/structuring considerations

The vehicle choice shapes governance flexibility, cost, tax efficiency and the ease of eventual exit. For most cross‑border joint venture spain arrangements, the practical shortlist is the SL, the SA, a branch, a contractual JV, or a cross‑border holding structure sitting above a Spanish operating entity.

Corporate form: pros and cons for tech & life sciences

The Sociedad Limitada (SL) is the default choice for most private JVs and minority investments. It offers lower minimum capital, flexible governance, and restrictions on the free transfer of shares that suit closely held ventures, a natural fit for founder‑led tech companies and early‑stage life‑sciences collaborations. The Sociedad Anónima (SA) provides greater flexibility for complex share classes and future capital‑markets access, making it preferable where an IPO exit is contemplated or where multiple investor tranches are expected; it carries a higher minimum share capital requirement as set by the Ley de Sociedades de Capital.

• SL. Lower cost, transfer restrictions favour minority protection, flexible statutes, ideal for two‑party JVs and venture‑style minority investments.
• SA. Suited to larger ventures, differentiated share classes and IPO‑ready structures; more formal governance and higher minimum capital.
• Branch. Useful for limited market presence but exposes the parent to permanent‑establishment and liability considerations.
• Contractual JV. Fastest and lightest for co‑development or R&D collaboration without a separate legal entity; relies wholly on the contract for governance and IP allocation.
• Cross‑border holding. A holdco layer can rationalise tax, financing and exit, and may assist in FDI structuring where legitimately available.

Tax considerations: PE risk, withholding and R&D incentives

Tax structuring should be modelled before the vehicle is fixed. The Agencia Tributaria administers corporate income tax, withholding on dividends, interest and royalties, and the rules that determine whether a foreign investor’s activities create a permanent establishment (PE) in Spain. A contractual JV or a branch can inadvertently create PE exposure for a foreign party; an incorporated SL or SA generally provides cleaner separation. Spain also offers R&D and innovation tax incentives that can materially improve the economics of a tech or life‑sciences JV, these should be factored into the business plan and, where relevant, protected in the shareholder agreement so that the benefit is not lost on a change of activity.

Confirm applicable tax rates and withholding treatment against the current legislation and the relevant double‑tax treaty before agreeing distribution mechanics.

Financing and capital contributions

How the parties fund the venture affects control, dilution and downstream returns. Contributions may take the form of cash, contributed IP or assets in kind, shareholder loans, or a mix. In‑kind contributions of IP require careful valuation and, in an SA, are generally subject to independent‑expert valuation requirements. Draft the capital‑contribution and future‑funding mechanics precisely: specify who funds follow‑on rounds, the consequences of failure to fund (dilution or default provisions), and whether shareholder loans convert or rank ahead of equity. For minority investments spain, anti‑dilution protection and pre‑emption rights are the primary defence against value erosion in later financing rounds.

Drafting the joint venture agreement Spain, clause playbook

The shareholder or joint venture agreement Spain document is where commercial intent becomes enforceable. For cross‑border deals, it must be coordinated with the company’s articles (estatutos) because certain protections are only fully effective against third parties when reflected in the statutes filed at the Commercial Registry (Registro Mercantil). The three pillars are governance, minority protection and exit.

Governance and control: board composition, observer rights, reserved matters

Governance clauses allocate day‑to‑day and strategic control. Board composition should reflect the economic split but also protect the minority’s ability to be heard, through a board seat, an observer right, or both. Reserved matters are the heart of minority governance: a defined list of strategic decisions that cannot proceed without the investor’s consent or a qualified majority. Typical reserved matters include changes to the business plan, issuance of new shares, incurrence of debt above a threshold, related‑party transactions, disposal of core IP, and any change of control.

Minority protections: information rights, vetoes, ROFR/ROFO, tag/drag, anti‑dilution

Because Spanish law provides only a limited statutory baseline of minority protection, contractual protections carry the weight. Strategic investors typically negotiate a broader veto list geared to operational and IP decisions, while financial investors focus on value protection and exit. Core minority protections include:

• Information rights. Regular management accounts, budgets and inspection access.
• Reserved‑matter vetoes. Consent rights over the defined list of strategic decisions.
• ROFR / ROFO. First refusal or first offer on any transfer of shares by the majority.
• Tag‑along. The right to sell on the same terms if the majority sells.
• Drag‑along. The ability to require minorities to join a sale above a threshold.
• Anti‑dilution. Pre‑emption rights and, where negotiated, price protection on down rounds.

Exit mechanics & valuation: formulas, IPO vs buyout, deadlock resolution

Every JV agreement should assume the parties will one day part. Exit provisions should specify the mechanism (buyout, trade sale, or IPO), the valuation methodology (independent expert, agreed multiple, or a formula), and the trigger events. Put and call options give a minority a defined route to liquidity and a majority a route to consolidation. Deadlock, a genuine risk in 50/50 JVs, needs a clear escalation ladder: senior‑executive negotiation, then mediation, then a defined tie‑breaker such as a Russian‑roulette or Texas shoot‑out mechanism, or a casting vote.

Where an IPO is a realistic outcome, the vehicle should be an SA and the agreement should address lock‑ups, drag rights and registration mechanics; the CNMV governs public‑market disclosure and listing obligations if the company is later floated.

IP, employment, clinical data & operational issues for tech and life sciences JVs

Operational integration is where many cross‑border joint ventures succeed or fail. In tech and life‑sciences deals, IP ownership, workforce transfer and clinical/regulatory data access are the recurring flashpoints.

IP ownership & licensing structure

Distinguish clearly between background IP (what each party brings) and foreground IP (what the JV creates). Background IP is typically retained by its owner and licensed to the JV on defined terms; foreground IP is usually owned by the JV, with fallback licences to each party on exit. For a life sciences joint venture spain arrangement, patent prosecution, freedom‑to‑operate and the treatment of know‑how must be addressed expressly. Specify licence scope, field of use, sublicensing rights, and what happens to each IP category on termination, a poorly drafted IP exit clause can strand a party’s most valuable asset inside a defunct vehicle.

Employment & secondment vs transfer

Where employees move into the JV, Spanish rules on the transfer of undertakings (succession of undertaking under the Estatuto de los Trabajadores) apply. A transfer of a business or autonomous production unit triggers automatic subrogation of employees on their existing terms, together with information and consultation obligations toward employee representatives and, where applicable, the works council. This affects timing and cost. An alternative is secondment, under which employees remain employed by the original party and are assigned to the JV, often simpler for a limited co‑development phase, but with its own governance and cost‑allocation questions. Build HR warranties and a clear transfer/secondment plan into the transaction, and allow for consultation periods in the timetable.

Clinical / regulatory data access

In pharma and MedTech JVs, access to clinical‑trial data, regulatory dossiers and marketing‑authorisation files can be as important as the underlying IP. Address who holds the marketing authorisation, how the parties access AEMPS filings, and how patient and clinical data are shared consistently with AEPD requirements. Because health data is sensitive, the data‑sharing architecture, controllership, safeguards and international transfers, should be documented before any data flows between the parties.

Negotiation playbook & transaction process checklist (pre‑signing to closing)

A disciplined process protects value and prevents regulatory surprises. The typical sequence runs from due diligence through pre‑filing to signing and, after conditions are satisfied, to closing. Regulatory and tax due diligence should run in parallel with the commercial workstream so that FDI and competition strategy is set before heads of terms are finalised.

Interim protections matter. Between signing and closing, a standstill and exclusivity arrangement keeps the target from soliciting competing offers, while conduct‑of‑business covenants preserve the value being acquired. For minority investments, reps and warranties should be calibrated to the information genuinely available to a non‑controlling buyer, with an appropriate indemnity package and, where used, an escrow or holdback to secure recovery.

Comparison table, joint ventures Spain vs minority investment

Conclusion: practical next steps

Joint ventures Spain and minority investment structures are the pragmatic tools of the 2026 market, they let foreign investors participate in a buoyant, regulated economy without the friction of a full acquisition, provided the structuring, FDI strategy and governance drafting are done early and correctly. The decisive factors are choosing the right vehicle, mapping regulatory exposure before heads of terms, and negotiating minority protections and exit mechanics that actually work under Spanish law. Seek pre‑filing regulatory advice on FDI and competition before you commit to a structure, and align the shareholder agreement with the company’s statutes so protections are enforceable. To identify the right transaction team, see Spain M&A: M&A lawyers & practice (Spain).

This article is general information on structuring cross‑border joint ventures and minority investments in Spain and is not legal, tax or regulatory advice. Rules and thresholds change; obtain jurisdiction‑specific advice before acting.

Sources

1. BOE, Boletín Oficial del Estado
2. EUR‑Lex, Regulation (EU) 2019/452 (FDI screening framework)
3. Ministerio de Industria y Turismo, Foreign Investment guidance
4. CNMC, Comisión Nacional de los Mercados y la Competencia
5. AEPD, Agencia Española de Protección de Datos
6. CNMV, Comisión Nacional del Mercado de Valores
7. Agencia Tributaria, Spanish Tax Agency
8. AEMPS, Agencia Española de Medicamentos y Productos Sanitarios